Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.

One of the longest-running companies involved in diabetes technology is Medtronic Diabetes, which has had a twisting pathway in its product pipeline over the years. The company has been the leader in ...

WASHINGTON--Patients with type 1 diabetes who use Medtronic's MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a ...

The FDA has expanded its indication for Medtronic’s Guardian Sensor 3, allowing patients to wear the sensor on their upper arm. The sensor is part of Medtronic’s MiniMed 670G system, and is currently ...